PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia

s | 51 PM415 Clozapine-induced anemia and thrombocytosis Hanson Park, So Yeon Jeon St. Andrew’s Hospital, Republic of Korea Abstract Objective of the study: Clozapine is one of well-known antipsychotics which causes hematologic adverse effects, specifically neutropenia and agranulocytosis (1–3% of patients). We found a rare case of thrombocytosis and anemia after the re-administration of clozapine. Methods used: We reviewed the documents about clozapine induced hematologic adverse-effects, esp. anemia and thrombocytosis. And we summarized the case of anemia and thrombocytosis after re-start of clozapine by the result of hematologic work-up and clinical responses of it. Summary of results: Reports about blood dyscrasias like anemia and thrombocytosis after clozapine treatment has been extremely rare. In some cases, re-challenge of clozapine could lead to hematopoietic abnormality related to thrombocytopenia or thrombocytosis, which is may be a result of an immune reaction. The details of hematologic finding are shown in the graph. Conclusions reaches: This case report suggest that clinician should monitor platelet count after the re-treatment of clozapine.